ARTIST
Regimen
- Experimental
- adjuvant XP x2 + radiotherapy + XP x2 (chemoradiotherapy)
- Control
- adjuvant XP (capecitabine + cisplatin) x6 cycles
Population
D2-resected gastric cancer
Key finding
3y DFS 78.2% (XPRT) vs 74.2% (XP), HR 0.740 (95% CI 0.520-1.050, P=0.0922, NS); OS HR 1.130 (NS); subgroup benefit in node+ and intestinal Lauren
Source: PMID 25559811
Timeline
Guideline citations
- NCCN GASTRIC (p.90)
- CSCO GASTRIC 2025 (p.63)⚠️ OCR source